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ARTICLE
Evaluation of integrin αvβ6 cystine knot PET tracers
to detect cancer and idiopathic pulmonary ﬁbrosis
Richard H. Kimura1, Ling Wang2,13, Bin Shen1,13, Li Huo2,13, Willemieke Tummers1,13, Fabian V. Filipp 3,4,13,
Haiwei Henry Guo 1,13, Thomas Haywood1, Lotﬁ Abou-Elkacem1, Lucia Baratto1, Frezghi Habte1,
Rammohan Devulapally1, Timothy H. Witney1, Yan Cheng1, Suhas Tikole3,4,5, Subhendu Chakraborti 1,
Jay Nix 6, Christopher A. Bonagura7, Negin Hatami1, Joshua J. Mooney 8, Tushar Desai 9, Scott Turner10,
Richard S. Gaster1, Andrea Otte 1, Brendan C. Visser11, George A. Poultsides11, Jeffrey Norton11, Walter Park8,
Mark Stolowitz1, Kenneth Lau1, Eric Yang12, Arutselvan Natarajan 1, Ohad Ilovich1, Shyam Srinivas1,
Ananth Srinivasan1, Ramasamy Paulmurugan1, Juergen Willmann1, Frederick T. Chin1, Zhen Cheng 1,
Andrei Iagaru1, Fang Li2 & Sanjiv S. Gambhir 1
Advances in precision molecular imaging promise to transform our ability to detect, diagnose
and treat disease. Here, we describe the engineering and validation of a new cystine knot
peptide (knottin) that selectively recognizes human integrin αvβ6 with single-digit nanomolar
afﬁnity. We solve its 3D structure by NMR and x-ray crystallography and validate leads with 3
different radiolabels in pre-clinical models of cancer. We evaluate the lead tracer’s safety,
biodistribution and pharmacokinetics in healthy human volunteers, and show its ability to
detect multiple cancers (pancreatic, cervical and lung) in patients at two study locations.
Additionally, we demonstrate that the knottin PET tracers can also detect ﬁbrotic lung disease
in idiopathic pulmonary ﬁbrosis patients. Our results indicate that these cystine knot PET
tracers may have potential utility in multiple disease states that are associated with upre-
gulation of integrin αvβ6.
https://doi.org/10.1038/s41467-019-11863-w OPEN
1 Department of Radiology, Stanford University, Stanford, CA 94305, USA. 2 Department of Nuclear Medicine, Peking Union Medical College, Beijing 100730,
China. 3 Cancer Systems Biology, Institute of Computational Biology, Helmholtz Zentrum München, Ingolstädter Landstraße 1, D-85764 München, Germany.
4 School of Life Sciences Weihenstephan, Technical University München, Maximus-von-Imhof-Forum 3, D-85354 Freising, Germany. 5 Department of
Chemistry, Mississippi State University, Mississippi State, MS 39762, USA. 6Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, CA
94720, USA. 7 Art Robbins Instruments, Sunnyvale, CA 94089, USA. 8Department of Medicine, Stanford University, Stanford, CA 94305, USA.
9Department of Internal Medicine, Stanford University, Stanford, CA 94305, USA. 10 Pliant Therapeutics, Redwood City, CA 94063, USA. 11 Department of
Surgery, Stanford University, Stanford, CA 94305, USA. 12 Department of Pathology, Stanford University, Stanford, CA 95305, USA. 13These authors
contributed equally: Ling Wang, Bin Shen, Li Huo, Willemieke Tummers, Fabian V. Filipp, Haiwei Henry Guo. Correspondence and requests for materials
should be addressed to S.S.G. (email: sgambhir@stanford.edu)
NATURE COMMUNICATIONS |         (2019) 10:4673 | https://doi.org/10.1038/s41467-019-11863-w |www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Through the use of high afﬁnity ligands, positron emissiontomography (PET) imaging is an effective way to distin-guish between diseased and healthy tissues. Accumulation
of PET tracers in tissues provides a way to image the molecular
signature of disease, such as cancer by targeting overexpressed cell
surface proteins. Aberrant protein expression also occurs in other
diseases such as idiopathic pulmonary ﬁbrosis (IPF), a chronic,
progressive ﬁbrotic interstitial lung disease (ILD) of unknown
cause1. Analogous to many cancers, prognosis in IPF is poor with
a mean survival of ~3–5 years2.
Integrin receptors are the focus of extensive efforts aimed at the
development of PET tracers3–6. Integrins are a family of proteins
that mediate cellular adhesion to extracellular matrix (ECM)
proteins. In normal cells, integrins transduce signals from the cell
surface to support gene expression of multiple proteins that
regulate differentiation, migration, proliferation, and apoptosis7.
In certain diseases such as cancer, the expression of some
integrins become dysregulated8. In a well-studied example,
integrin αvβ3 (the angiogenesis integrin) is highly overexpressed
on both tumor-neovasculature, and the surface of some human
cancer cells8. Other integrins, such as αvβ1 and αvβ5 can be bio-
markers of speciﬁc types of cancer8. Similarly, ﬁbrosing diseases
are known to express unique subsets of integrins2,9–11. Expression
expression proﬁles of different integrins have shown prognostic
value, so detecting them in vivo may be useful for diagnosing,
managing, or treating disease8,12,13. A number of PET tracer and
therapeutics, such as the RGD derivatives, that target integrin
receptors are currently undergoing clinical trials5,12.
A different member of the integrin family, αvβ6, is over-
expressed on the surface of many types of cancer cells14. Integrin
αvβ6 overexpression has been conﬁrmed in oral squamous cell
carcinoma15, pancreatic ductal adenocarcinomas (PDAC)16,
intestinal gastric carcinomas16, ovarian cancer17, and stage III
basal cell carcinoma18. Integrin αvβ6 overexpression is a prog-
nostic indicator of reduced survival in colon carcinoma19, non-
small cell lung cancer20, cervical squamous carcinoma21, and
gastric carcinoma22. Furthermore, αvβ6 expression is associated
with increased liver metastasis of colon cancer23. In contrast, its
expression is undetectable in many normal tissues including
ovary17, kidney, lung, skin15, and pancreas16. In recent studies,
immunohistochemical analyses (IHC) revealed robust expression
of αvβ6 in PDAC compared to cancers of other systems14,16.
Expression of αvβ6 was reported to be signiﬁcantly higher in
PDAC compared to chronic pancreatitis, and its expression was
observed in tumor-positive lymph nodes24. In well differentiated
pancreatic tumors, elevated levels of αvβ6 were reported in 100%
of the samples (n= 34) by IHC14,16. Currently, different research
groups, including ours, are developing peptide-based PET tracers
to image αvβ6 for cancer detection25–27.
Integrin αvβ6 has also been the subject of numerous studies as a
potential biomarker of ﬁbrotic ILD, which include IPF, non-
speciﬁc interstitial pneumonitis (NSIP), chronic hypersensitivity
pneumonitis (HP)2,28. αvβ6 is a potent activator of transforming
growth factor (TGF)β1, which enhances matrix deposition by
ﬁbroblasts in wound healing and ﬁbrosis29,30. In a recent study,
where a number of potential biomarker candidates were screened
by tissue IHC, only αvβ6 was found to be statistically associated
with a poor prognosis in ﬁbrotic ILDs. Levels of αvβ6 correlate
directly and signiﬁcantly to the risk of death from IPF. A 25-
month median survival was observed in patients with the highest
levels of αvβ6 expression2.
Targeted PET ligands created by directed evolution strategies
often demonstrate exquisite selectivity and high binding afﬁnity
their targets31,32. A given PET tracer’s pharmacokinetic proﬁle is a
function of its biochemical and biophysical characteristics, such as
the overall electrostatic charge and molecular weight. Cystine knot
peptides (knottins) are small (~4 kDa) peptides characterized by
three threaded disulﬁde bonds arranged in a topological knot; this
stabilizing core motif is known as a cystine knot31,33. Solvent
exposed loops, that can be bioactive, extend from this knotted
core. In our studies, we have engineered both high-afﬁnity antigen
recognition (KD~1 nM) and pharmacokinetic stabilizers into these
loops26. Since peptides are generally small, modiﬁcation of a single
amino acid in the framework could have a dramatic effect on
overall tracer pharmacokinetics. One advantage of the knottin
scaffold is that their backbone residues are highly variable such
that they can be ﬁne-tuned to greatly increase tumor uptake or
decrease renal uptake in mouse models26. In this study, we
developed several pharmacokinetically stabilized αvβ6 knottins and
evaluated their ability to image disease in living systems as [64Cu]
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA),
[68Ga]2,2′-(7-(1-carboxy-4-((2,5-dioxopyrrolidin-1-yl)oxy)-4-
oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid (NODAGA) and
[18F]ﬂuoropropyl (FP) PET tracers.
Here, we describe the development and validation of knottin
PET tracers that selectively recognizes human αvβ6 with single-
digit nanomolar afﬁnity. We solve its 3D structure by NMR and
x-ray crystallography and validate leads with 3 different radi-
olabels in pre-clinical models of cancer. We evaluate the lead
tracer’s safety and performance in healthy human volunteers and
show its ability to detect multiple cancers (pancreatic, cervical,
and lung). Additionally, we demonstrate the knottin PET tracer’s
ability to detect ﬁbrotic lung disease in IPF patients. Our studies
show the cystine knot PET tracers’ potential in multiple disease
states associated with elevated αvβ6.
Results
Development of the lead candidate R01-MG. Three cystine knot
peptides (R01, R01-MG, R01-MR) were engineered for stability,
and high-afﬁnity molecular recognition of human αvβ6. Equili-
brium binding assays indicated that all variants bind αvβ6 with
low single-digit nanomolar binding afﬁnity (KD~1 nM, Supple-
mentary Fig. 1). As a result of comparative imaging studies
in vivo, R01-MG emerged as the lead translational candidate
(Fig. 1a). It was produced by cGMP solid phase peptide synthesis,
and its mass was veriﬁed by MALDI-TOF-MS (Supplementary
Table 1). In addition, the three-dimensional (3D) 1H-NMR
solution structure of R01-MG provided evidence that the cystine
knot structural element, which deﬁnes knottin peptides, was
conserved throughout the directed evolution process (Fig. 1b,
Table 1). Furthermore, x-ray crystallography studies conﬁrmed a
disulﬁde bond pattern consistent with the cystine knot motif
(Fig. 1c, Supplementary Fig. 2, Table 2). Competition binding
assays demonstrated that the N-terminus imaging label, located
~20 Å from the RTDL integrin-recognition motif in active loop-1,
did not adversely affect the tracer’s ability to bind αvβ6 with high-
afﬁnity. The half-maximal inhibitory concentration (IC50) values
for the unlabeled precursor and FP-labeled standard were 0.61 ±
0.31 nM and 0.56 ± 0.46 nM S.D., respectively (Fig. 1c insert,
Supplementary Fig. 3).
In order to select the most promising ligand for clinical
translation, [64Cu]DOTA-R01, [64Cu]DOTA-R01-MR, and [64Cu]
DOTA-R01-MG were ﬁrst evaluated in mouse models with αvβ6
expressing BxPC3 pancreatic cancer xenografts (Fig. 1d, Supple-
mentary Fig. 4, and Table 3). At 1 h post injection (p.i.),
accumulation of tracer in the tumors were comparable at ~3%
injected dose per gram (%ID g−1) across the variants (Table 3).
However, [64Cu]DOTA-R01-MR was eliminated from further
consideration because its kidney uptake (~90 %ID g−1) was
approximately 3-fold higher than the other two candidates (~30 %
ID g−1, Table 3 and Supplementary Table 2). Based on these
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Fig. 1 Summary of the knottin PET ligand. a Primary structure of lead candidate R01-MG. The engineered active loop-1 is shown in blue. The integrin avβ6
core binding motif, RTDLxxL, is shown in black. The framework residues are shown in gray. Cysteine residues are shown in yellow and the pattern of
disulﬁde bonds are indicated by the connecting lines. b Ensemble of 10 lowest energy three-dimensional 1H NMR of R01-MG structures. c Crystal structure
of non-radioactive reference standard, [19F]FP-R01-MG-F2, at <1 Å. The carbonyl oxygen of the ester is shown in cyan. The ﬂuorine atom is shown in red.
The methyl carbon is shown in black. The insert on top shows the RP-HPLC trace of R01-MG, and the radio-RP-HPLC trace of the puriﬁed clinical-grade PET
tracer [18F]FP-R01-MG-F2, respectively. The product is indicated by the asterisk. The insert on the bottom shows b the equilibrium binding curve of
between R01-MG expressed on yeast surface and soluble human integrin αvβ6 (KD= 1.24 ± 0.21 nM S.D.), and c the competition binding between unlabeled
R01-MG (IC50= 0.61 ± 0.31 nM S.D., circles) or the N-terminus labeled version [19F]FP-R01-MG-F2 (IC50= 0.56 ± 0.46 nM S.D., squares) vs. yeast surface
expressed R01-MG, respectively. d Comparison at 1 h post injection of the top 3 [64Cu]DOTA-labeled PET tracer candidates, R01 (black), R01-MR (white)
and R01-MG (gray). e Comparison at 1 h post injection of the [18F]FP labeled lead candidate R01-MG in integrin αvβ6 positive (cyan) vs. αvβ6 negative
tumor models (magenta, dashed circle in the ﬁgure). In vivo validation of the [68Ga]NODAGA-R01-MG at 1 h post injection (yellow). f Volume rendered
PET/CT images of [18F]FP-R01-MG (cyan) and [68Ga]NODAGA-R01-MG (yellow) in integrin avβ6 positive models at 1 h post injection. d–f The cyan
arrows point to the tumor. The letters K and B represent the kidneys and bladder, respectively. (d–f and Table 3, below) Box colors are colored legends that
cross-relate the images to the quantiﬁcation table
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initial studies, R01-MG was selected as the lead translational
candidate and evaluated as a radioﬂuorinated PET tracer.
[18F]FP-R01-MG-F2 was evaluated in pre-clinical models
with either human αvβ6-positive (~3.5 %ID g−1) or αvβ6-negative
(~0.5 %ID g−1) tumors (Fig. 1e, Supplementary Figs. 5 and 6).
Selective tracer uptake was demonstrated in the αvβ6 over-
expressing tumors (Table 3 and Supplementary Table 3).
Additionally, due to the widely adopted use and ubiquitous
availability of 68Ga for PET imaging, R01-MG was also evaluated
as [68Ga]NODAGA-R01-MG (Fig. 1e, f). [68Ga]NODAGA-R01-
MG demonstrated comparable tumor and organ uptake with
respect to the radioﬂuorinated version. At 1 h p.i., [68Ga]
NODAGA-R01-MG’s tumor uptake was 2.8 ± 0.3 %ID g−1.
Liver, muscle and kidney uptake was 1.2 ± 0.4 %ID g−1,
0.6 ± 0.1 %ID g−1 and 30.4 ± 5.5 %ID g−1, respectively (Table 3).
[18F]FP-R01-MG-F2 in healthy volunteers (Stanford). [18F]FP-
R01-MG-F2 (Supplementary Fig. 7) was administered intrave-
nously to ﬁve healthy male and female adult volunteers (Sup-
plementary Table 4). No adverse effects were reported. Oxygen
levels, vital signs, and electrocardiography (ECG) readings were
normal (Supplementary Tables 5 and 6).
Maximum intensity projection (MIP) PET shows the biodis-
tribution of [18F]FP-R01-MG-F2 in a healthy volunteer (HV-1,
Fig. 2a and Supplementary Movies 1–3). Transaxial PET/CT
images show tracer distribution in the abdomen and brain
(Fig. 2b). [18F]FP-R01-MG-F2 was renally cleared (SUVmean ~ 15)
with uptake noted in the stomach (SUVmean ~ 10) and small
intestines (SUVmean ~ 9, Supplementary Table 7). IHC conﬁrmed
expression of αvβ6 in normal stomach and small intestine tissues
(Fig. 2c). [18F]FP-R01-MG-F2 reached peak levels in blood within
~1–3 min after administration (Supplementary Table 8). Uptake
in most normal organs including the lung and liver were relatively
low (SUVmean < 1, Fig. 2c). Muscle SUVmean ~ 1.5 and pancreatic
uptake was slightly higher at 1 h p.i. (SUVmean ~ 2). Tracer
accumulation was elevated in the pituitary gland (SUVmean ~ 4,
1 h p.i.) and the large intestines (SUVmean ~ 3, 1 h p.i.). The
kidneys were the dose-limiting organ (SUVmean ~ 12, 1 h p.i.,
Supplementary Tables 7 and 9).
[18F]FP-R01-MG-F2 vs. [18F]FDG in pancreatic CA (Stanford).
[18F]FDG and [18F]FP-R01-MG-F2 were separately administered
on different days to a 61-year-old (y.o.) woman with pancreatic
cancer (Supplementary Table 10). MIP PET, PET/CT and volume
rendered PET/CT images show the biodistribution of [18F]FP-
R01-MG-F2 (Fig. 3a) and [18F]FDG (Fig. 3b) ~1 h p.i. Dynamic
PET of the abdominal region are quantiﬁed in Supplementary
Fig. 8. The biodistribution of [18F]FDG and [18F]FP-R01-MG-F2
at 1 h p.i. are compared in Supplementary Fig. 9.
[18F]FP-R01-MG-F2 was distributed broadly throughout the
tumor (ROI ~ 8000 mm3) and resulted in a SUVmean of 6.2 at 1 h
p.i. (Fig. 3a, Supplementary Movie 4). Comparatively, a region of
focal [18F]FDG uptake (ROI ~ 3000mm3, SUVmean= 4.1) was
present adjacent to a biliary stent (Fig. 3b, Supplementary Movie 5).
Tumor uptake is also shown in the volume rendered PET/CT
images (Fig. 3a, b, right panels), where the cyan arrows point to
the tumor mass. Uptake of [18F]FP-R01-MG-F2 and [18F]FDG in
Table 2 X-ray crystallography data collection and
reﬁnement statistics
Data Collection [19F]FP-R01-MG-F2
Space group p212121
Cell dimensions (Å) 16.90 × 44.40 × 66.71
Resolution (Å) 1–36.8200
Rmerge 0.036
I/σI 32.3
Completeness (%) 94.1
Redundancy 29
Reﬁnement
Resolution (Å) 1–36.8200
No. reﬂections. 24257
Rwork/Rfree 0.3590/0.3640
B-factors 10.1520
R.M.S. deviations 0.032
Structural Reﬁnement Statistics. The table corresponds to the crystal structure shown in Fig. 1c
Table 3 PET quantiﬁcation table
Legend PET Tracer αvβ6 Tumor Liver Kidney Muscle T:M Ratio
(average % injected dose gram−1 ± SD)
[64Cu]DOTA-R01 (+) 3.07 ± 0.17 2.26 ± 0.11 30.30 ± 2.33 0.433 ± 0.008 7.09 ± 0.27
[64Cu]DOTA-R01-MR (+) 3.45 ± 0.34 4.63 ± 0.09 89.95 ± 3.64 0.536 ± 0.004 6.43 ± 0.58
[64Cu]DOTA-R01-MG (+) 2.74 ± 0.35 2.14 ± 0.38 28.35 ± 2.61 0.472 ± 0.003 5.80 ± 0.72
[18F]FP-R01-MG (+) 2.72 ± 0.60 0.88 ± 0.10 15.10 ± 1.28 0.490 ± 0.116 5.59 ± 0.55
[18F]FP-R01-MG (−) 0.47 ± 0.12 0.87 ± 0.08 22.36 ± 1.50 0.455 ± 0.057 1.02 ± 0.19
[68Ga]NODAGA-R01-MG (+) 2.78 ± 0.30 1.20 ± 0.35 30.05 ± 5.51 0.589 ± 0.124 4.86 ± 1.04
PET image quantiﬁcation of tissues including the tumor, liver, muscle, and kidneys. Tumor-to-muscle ratio is indicated by T:M Ratio. The table lists the average value ± the standard deviation (SD, n= 3).
Source Data are provided as a Source Data File
Table 1 NMR reﬁnement statistics
NMR distance and dihedral constraints R01-MG
Distance constraints
Total NOE 225
Intra-residue 2
Inter-residue 84
Sequential (|i - j|= 1) 86
Medium -range (|i - j| < 4) 42
Long-range (|i - j| > 5) 97
Total dihedral angle restraints
ϕ 35
ψ 37
Structure statistics
Average pairwise r.m.s. deviation based on an ensemble of
20 structures (Å)
0.322
Structural Reﬁnement Statistics. The table corresponds to the NMR structure shown in Fig. 1b
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the liver exhibited SUVmeans of 0.9 and 2.9, respectively, at 1 h p.i.
SUVmeans of [18F]FP-R01-MG-F2 in the stomach and small
intestines were 22.9 and 10.7, respectively, at 1 h p.i. In
comparison, SUVmeans of [18F]FDG in the stomach and small
intestine at 1 h p.i. were 0.16 and 2.5, respectively. IHC analysis of
resected tumor tissue conﬁrmed high levels of αvβ6 (Fig. 3c).
[68Ga]NODAGA-R01-MG in cancer patients (PUMC). [68Ga]
NODAGA-R01-MG was administered to two adult male patients
(lung and pancreatic cancer) and four adult female patients (three
cervical and one pancreatic cancer) who were diagnosed with
cancer, as conﬁrmed by tissue biopsy (Figs. 4 and 5, Supple-
mentary Table 11). Sequential MIP PET images of a
representative study subject acquired from 9 to 61 min after
intravenous tracer administration (Fig. 4a) show comparable
pharmacokinetics and biodistribution between [68Ga]-R01-MG
and the radioﬂuorinated version, [18F]FP-R01-MG-F2. Similarly,
the 68Ga-labeled knottin PET tracer also accumulated in the
pituitary gland (Fig. 4b). ROI analysis of PET/CT images (Figs.
4c, d, Fig. 5a, Supplementary Figs. 10 and 11) show that [68Ga]-
R01-MG rapidly cleared via the kidneys, which was the dose-
limiting organ (Supplementary Table 12). The average kidney
SUVmean was 19.92 ± 2.23 at ~1 h p.i. Notable uptake and
retention of the tracer occurred in the stomach and small intes-
tines where the average SUVmeans were 8.87 ± 6.52 and 7.06 ±
2.74, respectively. The SUVmean of [68Ga]-R01-MG in normal
portions of pancreas was 1.79 ± 0.47 (n= 5). The average uptake
0
0 5
20SUV-torso
5 min
a
b c
60 min 120 min
SUV-head
Fig. 2 [18F]FP-R01-MG-F2 PET imaging of ﬁve healthy human volunteers. a Representative whole-body [18F]FP-R01-MG-F2 maximum intensity projection
(MIP) PET images of a healthy volunteer (50-year-old male) show the biodistribution of PET tracer at ~ 5, 60, and 120min post injection (p.i.). Focal uptake
near the elbow and between the legs are the site of intravenous injection, and a tube containing the reference calibration standard, respectively. b Axial and
coronal PET/CT images of the same healthy volunteer at 1 h p.i. Close-ups of the chest and abdominal regions show the heart (SUVmean ~ 0.9), liver
(SUVmean ~ 0.8), lung (SUVmean ~ 1.3), pancreas (SUVmean ~ 1.9), stomach (SUVmean ~ 12.6), small intestines (SUVmean ~ 7.8), kidneys (SUVmean ~ 14.3),
and bladder (5.9). Accumulation of the tracer is evident in the pituitary gland (SUVmean ~ 5). c H&E staining (top left) and integrin αvβ6 (top right and
bottom) immunohistochemical analysis of healthy stomach and small bowel tissue, where uptake was relatively high (Supplementary Table 7, below),
shows expression of integrin αvβ6 on the luminal (Lu) side of these organs. Scale bars on the 1x and 10x images represent 2.5 cm and 250mm, respectively
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in pancreatic cancer was SUVmean= 4.2 ± 0.1 (Fig. 4 and Sup-
plementary Fig. 12, Supplementary Movies 6 and 7). In one
pancreatic cancer patient, a continuous band of tracer uptake
occurred in a portion of the pancreas that spanned the head,
uncinate process, neck, and tail (Fig. 4d). Here, the majority of the
tumor mass occurred in the neck of the pancreas, but tracer
uptake was seen in only a portion of that enlarged mass. The
pathology report indicated moderately to poorly differentiated
pancreatic adenocarcinoma, as well as a signiﬁcant amount of
necrosis in that tissue. H&E staining and IHC conﬁrmed the
expression of αvβ6 in the viable parts of the tumor (Fig. 4e).
In cervical cancer patients, relatively low tracer uptake in the
lower large intestines (SUVmean= 1.54 ± 0.28) allowed for
straightforward detection of cervical tumor where the average
SUVmean= 4.79 ± 0.37 (Fig. 5, Supplementary Fig. 13, Supple-
mentary Movies 8 and 9). Comparatively, [18F]FDG accumulated
0 SUV-knottin
a
b
c
5
0 SUV-FDG 2
Fig. 3 [18F]FP-R01-MG-F2 PET imaging of pancreatic cancer. a [18F]FP- R01-MG-F2 and (b) [18F]FDG images, from left to right, show MIP, CT, PET/CT
(axial and coronal) and volume rendered PET/CT (full and magniﬁed) images of a 71-year-old female pancreatic cancer patient at ~60min post injection.
The liver, kidneys, small intestines, stomach and spleen are denoted by Lv, Kd, SI, St, and Sp, respectively. The cyan arrow points to the tumor.
a Accumulation of [18F]FP- R01-MG-F2 at the head of the tumor is shown by the cyan arrow (SUVmean= 6.3). PET/CT images demonstrate several regions
of relatively high accumulation including the kidneys, the main clearance route, and the stomach (St), small intestines (SI) where integrin αvβ6 is expressed.
b An area of focal [18F]FDG uptake (SUVmean= 2.3) which is located within the tumor coincides with a biliary stent (white tube) that is apparent in the CT
image. The tracer is seen draining out of the kidney (Kd) through the ureter and collecting in the bladder in the MIP, and volume rendered PET/CT images.
c From left to right, H&E staining and IHC analysis of the resected pancreatic mass, which included some healthy pancreatic tissue. A section of normal
pancreas (left) and a section of malignant tissue (right) are shown. Scale bars on the 1x and 10x images represent 2.5 cm and 250mm, respectively
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to similar levels (SUVmean= 4.1) in the tumor of the second
cervical cancer patient (Supplementary Fig. 13). H&E staining
and IHC conﬁrmed the expression of αvβ6 in the larger diffuse
cancer cells shown in the tissue slice (Fig. 5b). Additionally, in
one patient with lung cancer, very low uptake in the normal lung,
SUVmean= 0.41 ± 0.11, led to high contrast of a lung tumor
(Fig. 5c, SUVmean= 2.20) with a ~5:1 ratio of lung tumor to
normal lung.
[18F]FP-R01-MG-F2 in IPF and healthy lungs (Stanford). One
female and ﬁve male study subjects, 72.5 ± 1 y.o., who were
diagnosed with IPF by chest CT demonstrating a deﬁnite-UIP
pattern or lung tissue biopsy with a histopathologic UIP pattern,
were administered 5–10 mCi of [18F]FP-R01-MG-F2. Combined
PET/CT-based whole-lung contours were used to quantify PET-
tracer distribution in each lung. The left and right halves were
treated independently in the following analysis. Immediately
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Fig. 4 [68Ga]NODAGA-R01-MG biodistribution and PET imaging of pancreatic cancer. a Sequential MIP PET images of a 69-year-old female study subject
show the biodistribution of the tracer for up to ~1 h after intravenous administration. b PET/CT image of the brain shows focal uptake of the tracer in the
pituitary gland. c ROI analysis of the representative patient shown above. The following organs are shown: brain (Br), pituitary gland (Pt), breast (Brs),
lower large intestine (LLI), small intestine (SI), stomach (St), upper large intestine (ULI), heart wall (HW), heart contents (HC), kidney (Kd), liver (Lv), lung
(Ln), muscle (Ms), red marrow (RM), osteogenic cells (Bn), skin (Sk), spleen (Sp), thymus (Tm), thyroid (Tr), bladder (Bl), and total body (TB). d Coronal
and axial PET/CT images (left and center) and volume rendered PET/CT image (top right) acquired from a patient diagnosed with pancreatic cancer. The
arrows indicate the location of the tumor. High uptake is observed throughout most of the pancreas including the head (SUVmean ~ 3.1), uncinate process,
neck and tail (SUVmean ~ 4.4). Comparatively, the SUVmean= 1.8 ± 0.5 S.D. for normal pancreas (n= 5). e IHC conﬁrms integrin αvβ6 expression in the
viable part of the tumor. Red box represents area shown at 14x magniﬁcation in image below. Pathology report indicated a large amount of necrosis in the
tumor. Scale bars on the unmagniﬁed and 14x images represent 2.5 cm and 250mm, respectively. Source data for panel c are provided in a Source Data ﬁle
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upon injection, a 15-min dynamic PET scans showed that the
tracer rapidly entered and cleared from the healthy portions of
the lungs (dark areas on CT), but accumulated and persisted in
the diseased portions of those same lungs (white or gray on CT,
Supplementary Movies 10–13). [18F]FP-R01-MG-F2 accumula-
tion was greatest in the most severely ﬁbrosed portions of the
lung or in those regions of the lung that clearly demonstrated the
UIP pattern by CT (Fig. 6a, b, magenta arrows, reticulation,
honeycombing, and basal/subpleural predominance).
IPF-5 is a 72 y.o. male IPF patient who was diagnosed by CT
with a deﬁnite-UIP pattern in 2015 (Fig. 6a). The highest levels of
[18F]FP-R01-MG-F2 were found in the basal and subpleural
regions of the lungs, consistent with the CT-UIP diagnosis as
shown by the high degree of reticulation and honeycombing
(magenta and cyan arrows). In contrast, the healthy portions of
IPF-5’s lungs were relatively devoid of the PET tracer (white
arrows). The SUVmeans for the entire left and right lungs were
2.44 ± 1.16 and 1.90 ± 1.11, respectively (Fig. 7, Supplementary
Table 13). Due to the heterogenous distribution of ﬁbrosis in
ILDs, the extent of disease may be quantiﬁed by the SUVrange
(SUVmax − SUVmin, 6.82 ± 0.14 S.D.) as well as the fractional
amount of damaged lung tissue (Supplementary Fig. 14B). While
the SUVmaxs for the left and right lungs were 6.93 and 7.07, the
lung regions most severely affected by the disease are
comprehensively described by the distribution of SUVs (SUV
histogram) in the upper part of the SUVrange (Fig. 6d). For the left
lung, ~18% of the SUVs were between 3 and 3.9, while ~10% of
the SUVs were >4 as shown in the PET tracers SUV histogram
(Supplementary Fig. 14B) and a summary of SUV metrics in the
knottin PET tracer’s ﬁbrosis spectrum (Supplementary Table 13).
For the right lung, ~13% of the SUVs were between 3 and 3.9,
while ~5% were >4.
IPF-4 is a 72 y.o. male IPF patient who received a left lung
transplant at Stanford Hospital in 2016. (Fig. 6b). Chest CT shows
extensive ﬁbrosis in the native right lung where [18F]FP-R01-MG-
F2 accumulation was high and sustained (Fig. 6b). Accumulation
of the PET tracer correlated with the CT-based UIP pattern of
ﬁbrosis in the right lung, where the SUVmean and SUVrange were
1.89 ± 0.74 and 5.10, respectively. In contrast, the SUVmean and
SUVrange of the transplanted left lung were 0.93 ± 0.38 and 4.34,
respectively (Fig. 7, Supplementary Fig. 14A, and Supplementary
Table 13). IPF-4’s transplanted left lung is relatively devoid of the
PET tracer, and the CT images are also consistent with a typical
healthy lung (Fig. 6b).
In order to calibrate the IPF lungs to a reference standard, the
lungs of the ﬁve healthy volunteers were similarly quantiﬁed. The
within-subject intraclass correlation between lungs in healthy
volunteers was 0.99 compared to 0.76 in IPF patients34. Due to
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Fig. 5 [68Ga]NODAGA-R01-MG PET imaging of cervical cancer and lung cancer. a Coronal (top left), sagittal (top right) and axial (bottom left) planes of
PET/CT images of a 47-year-old cervical cancer patient shows tracer accumulation in the tumor (cyan arrow). Bl, Kd, Lv, SI, Sp, and St refer to the bladder,
kidneys, liver, small intestine, spleen and stomach, respectively. b H&E staining and IHC analysis conﬁrm expression of integrin αvβ6 by the larger diffuse
cancer cells. Integrin αvβ6 was not expressed by the normal cells of the cervix surrounding the tumor. Red box represents area shown at 15x magniﬁcation
in image below. Scale bars on the 1x and 15x images represent 2.5 cm and 250mm, respectively. c Coronal (left), axial (middle) and sagittal (right) planes
of PET/CT Images of a 70-year-old patient diagnosed with poorly differentiated squamous cell carcinoma of the lung (SUVmean= 2.2). The cyan arrow
points to the tumor. The healthy lung and heart are indicated by Ln and H, respectively
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the high degree of correlation between right and left lungs of
healthy volunteers and IPF patients, their right lungs were
compared to avoid the left lung transplant of IPF-4. A statistically
signiﬁcant difference (p= 0.0087) in PET-tracer level was found
between the set of healthy right lungs (average SUVmean= 0.92 ±
0.33, n= 5) versus the diseased right lungs of IPF patients
(average SUVmean= 2.04 ± 0.91, Fig. 7, n= 6). The lowest [18F]
FP-R01-MG-F2 levels occurred in the two youngest volunteers, 20
(HV-3) and 26-year old (HV-5), where their total-lung
SUVmeans= 0.76 ± 0.22 and 0.53 ± 0.20, respectively. For com-
parative purposes, the relatively pristine young lungs in these two
individuals served as an age-based SUV referential-baseline
(baseline-20 SUVmean= 0.67 ± 0.12, and normal distribution)
for comparison of all lung data reported in this study
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Fig. 6 [18F]FP-R01-MG-F2 PET imaging of lungs: IPF patients and healthy volunteers. a PET/CT images of IPF-5, a 72-year-old male IPF patient with a
deﬁnite-UIP pattern, as indicated by peripheral, basilar predominant reticulation and honeycombing (CT, top, cyan arrows). Correspondingly, the PET tracer
is concentrated in regions of greatest ﬁbrosis in the areas of high reticulation and honeycombing in the lung bases (PET, middle and PET/CT, bottom, cyan
arrows). In contrast, relatively healthy regions of the upper and anterior lungs show low tracer accumulation (PET/CT, bottom, white arrows). b PET/CT
images of a 72-year-old male IPF patient with a single transplanted (2016) left lung (white arrows), which is relatively devoid of the PET tracer. The ﬁbrotic
right lung (IPF) shows elevated PET tracer levels in areas that also correspond to the highly ﬁbrosed regions demonstrated on CT (PET/CT, bottom, cyan
arrows). c PET/CT images of the lungs of ﬁve healthy volunteers, varying in age from 20- to 48-year old. The group demonstrated a range of lower [18F]FP-
R01-MG-F2 accumulation in their lungs. d The dashed lines represent histograms of SUVs found within ROI contours of total lung. The upper histogram
represents the healthy volunteers (HV-1 to HV-5). The lower histogram (dashed blue line) represents patient IPF-5 shown in panel A. For comparative
purposes, the solid black curves in both (top and bottom graphs) represent baseline-20 SUVmean and normal distribution (BL-20 ND) derived from the two
youngest healthy volunteers in their 20 s (HV-3 and HV-5)
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(Fig. 6c–d, Supplementary Table 13). The SUV-histograms of
young lungs exhibited a Gaussian distribution (Fig. 6d) as
modeled by baseline-20’s normal distribution (Fig. 6d). In
contrast, the highest [18F]FP-R01-MG-F2 levels
(SUVmean= 1.41 ± 0.38) were found in HV-1, a 48-year-old
currently asymptomatic male, who is a long-term bird-owner.
Exposure to birds is a well-studied risk-factors for ﬁbrotic
ILDs35,36. The two remaining volunteers, both females in their
40s, showed mildly higher levels of [18F]FP-R01-MG-F2 relative
to baseline-20 (Fig. 6d, top, Supplementary Table 13).
Discussion
Our manuscript describes the complete process of developing and
translating a cystine knot PET tracer for detection of multiple
αvβ6-positive indications, including cancer and IPF. In both pre-
clinical small animal models and human clinical trial participants,
accumulation of the knottin PET tracers with αvβ6-positive
tumors and the ﬁbrotic portions of lungs was rapid, high, and
sustained, compared to healthy tissues. Human cancer was
detected in multiple regions of the body including the thorax
(lung cancer), upper abdomen (pancreatic cancer), and lower
abdomen (cervical cancer). Compared to very low background
levels of this tracer in healthy young lungs, elevated tracer levels
and a robust dynamic range of uptake were observed in the lungs
of patients diagnosed with IPF. Accumulation of our PET tracers
in most normal human tissues was generally low with notable
exceptions in the upper gut and pituitary gland. Our initial
ﬁndings suggest that the αvβ6 knottin PET tracers may ﬁnd broad
clinical application in the detection of diseases marked by over-
expression of αvβ6.
αvβ6 belongs to a subfamily of integrins called the RGD
integrins3,37. Proteins or peptides that contain RGD motif are
able to discriminate between different integrins by structural
differences in the amino acids that ﬂank the core RGD motif. The
foot and mouth disease virus (FMDV) evolved an RGD ﬂanking
sequence in a viral coat protein that selectively recognizes αvβ6
with high-afﬁnity, while molecularly ignoring the other integrins
such as αvβ3. Sutcliffe et al. have extensive experience developing
and translating different FMDV-based PET tracers38. Kraft et al.
and Nothelfer et al. utilized phage display to develop afﬁnity
ligands that recognize αvβ639,40. Recently, a simple disulﬁde-
stabilized peptide demonstrated modest uptake in head and neck
cancer27.
Cystine knot peptides engineered for selective, high-afﬁnity
molecular recognition of cancer markers have recently shown
promise in pre-clinical models, not only as PET tracers, but in
near infrared ﬂuorescence imaging, molecularly targeted ultra-
sound imaging, and photoacoustic imaging4,41,42. Studies of
knottin PET tracers have revealed that their pharmacokinetics are
highly tunable through simple amino acid substitutions in their
loops26. This pharmacokinetic versatility is one characteristic that
distinguishes cystine knot PET tracers from other peptide-tracers
such as the linear FMDV derivatives, simple cyclic peptides
(cyclo-RGD) or peptides that depend on their framework amino
acids (non-binding) for structural stability (triple helix bundle).
Comparatively, these simple linear or cyclic peptides have shown
improved pharmacokinetic proﬁles through chemical modiﬁca-
tion strategies such as dimerization and/or PEGylation38,43.
Three different imaging labels ([64Cu]DOTA-, [68Ga]
NODAGA-, and [18F]FP-) were used to evaluate the preliminary
set of high-afﬁnity knottins. Due to the relatively long half-life of
64Cu (12.7 h), [64Cu]DOTA- is well suited for initial screening of
ligands beyond 2 h so that we may survey tracer uptake in tumor
and normal tissues for up to 24 h after injection in pre-clinical
models. In this case, once we determined that there was no beneﬁt
to imaging beyond a certain timepoint, shorter-lived radio-
isotopes with higher positron yields and lower overall radiation
exposure were used. The equipment (e.g. cyclotron) and expertize
at Stanford radiochemistry facilitates the development of [18F]FP-
R01-MG-F2 and over a dozen clinical-grade 18F labeled PET
tracers for routine clinical use. However, the [68Ga]NODAGA-
R01-MG version evaluated in this study by PUMC hospital may
potentially be better suited for deployment due to the ubiquitous
availability of 68Ga (not requiring a dedicated cyclotron), and the
ease of radiosynthesis through a pre-prepared kit. For these
reasons, both the 18F and 68Ga versions were studied.
R01-MG PET tracers were evaluated in several different αvβ6-
positive cancers. In pancreatic cancer, accumulation of the PET
tracer, [18F]FP-R01-MG-F2 was rapid and remained high
throughout the study (SUVmean ~ 6 at 1 h p.i.). Here, we were
fortunate to have [18F]FDG data from a clinical PET/CT for
comparison. Accumulation of [18F]FDG by the tumor was con-
centrated (~3000 mm3, SUVmean ~ 4 at 1 h p.i.) near a biliary
stent which was implanted to mitigate tumor-compression of the
common bile duct. Comparatively in this same patient, the uptake
of [18F]FP-R01-MG was more uniformly distributed over a
greater tumor volume (~8000 mm3). The difference in uptake
proﬁles between the two classes of PET tracers probably reﬂects
the different activities that are targeted (glucose metabolism vs.
expression of ECM protein). In another pancreatic cancer
patient, we observed a continuous band of intense uptake of
[68Ga]NODAGA-R01-MG from the head of the pancreas
(SUVmean ~ 3.8) to the tail (SUVmean ~ 7), while the main tumor
mass was located at the neck of the pancreas. Interestingly, the
uptake did not occur throughout this entire tumor mass; tracer
accumulation occurred only within the craniad of the enlarged
mass as part of that continuous band of head-to-tail uptake. The
pathology report indicated signiﬁcant necrosis within the resected
mass, and αvβ6-positive IHC staining occurred only in the viable
part of the tumor. Pancreatic tumors in three patients were easily
discernable from their PET/CT images despite high tracer accu-
mulation in neighboring stomach and small intestine.
Accumulation of the knottin PET tracer was observed in the
primary tumors of cervical cancer patients (SUVmean ~ 5) where
uptake by neighboring lower bowel and uterus were relatively
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Fig. 7 Mean SUVs of healthy volunteers and IPF patients. Mean SUVs from
healthy volunteers and IPF patients are shown as circles and triangles,
respectively. The single transplanted lung in patient IPF-4 is shown as a
circle (far right). The right/left mean SUVs for patient IPF-3 were identical
and appear as a single triangle (Supplemental Table 13). The right/left
correlation is 0.90 and 0.70 for HVs and IPF patients, respectively. The
average SUVmeans ± S.D.s for the right lungs of HVs (n= 5) and the IPF
group (n= 6) is 0.92 ± 0.33 and 2.04 ± 0.91, respectively (p= 0.0087).
Source data are referred to in the Source Data File
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low. Due to the spatial resolution of the clinical PET scans, cer-
vical cancers were clearly delineated from adjacent bladder con-
taining urine-excreted knottin PET tracer. However, one caveat
comes from an early report that found a 10-fold higher expres-
sion of β6 integrin subunit’s mRNA in the stratum functionalis of
endometrial epithelium44. Much lower mRNA levels were
reported for the analogous specimen during the proliferative
phase endometrium, suggesting that αvβ6 levels may be in ﬂux
during the menstrual cycle. Finally, very low αvβ6 knottin PET
tracers accumulation in the upper thorax of normal subjects
allowed the detection of lung cancer in one patient (Fig. 5c).
This pilot clinical study with the knottin PET tracers for cancer
detection is limited mainly by the small number of cancer
patients. Therefore, recruitment of additional cancer patients is
ongoing as we aim to comprehensively evaluate these knottin
PET tracers for the cancers described here along with serous
ovarian cancer, and head and neck cancer, both of which
demonstrate elevated αvβ6 levels.
αvβ6’s role in TGF-β1 activation/signaling and in the patho-
genesis of ﬁbrotic diseases originating in lung and liver has been
well documented45–48. Inhibition of ﬁbrosis through molecular
recognition of αvβ6 has been achieved in the bleomycin mouse
model as well as in human clinical trials by a small molecule
inhibitor and several monoclonal antibodies28,49,50.
[18F]FP-R01-MG-F2 enables whole lung molecular assessment
of lung ﬁbrosis through expression of αvβ6, an ILD histological
marker that correlates with prognosis2. The knottin PET tracer’s
ﬁbrosis spectrum (Supplementary Table 13 provides information
about the extent of disease, with IPF patients exhibiting right-
ward shift of the SUVmean, extension of the SUVrange, and high-
SUV voxels populating the upper bins of the SUVhistogram. The
ability to non-invasively characterize active ﬁbrosis in ILDs
including IPF, based on molecular expression may be useful for
treatment planning and monitoring.
A lower range of [18F]FP-R01-MG-F2-accumulation was
observed in the lungs of healthy volunteers, which suggests that this
PET-tracer may be able to discern healthy individuals from IPF
patients51,52. Data for the low (healthy) end of the knottin PET
tracer’s ﬁbrosis spectrum were obtained from the two youngest
healthy volunteers (HV-3 and HV-5) in their twenties, who pro-
vided a hypothetical reference SUV baseline-20 mean and normal
distribution for young lungs. Statistical departure (z-score) away
from baseline-20 appears to correlate with the gradual transition
from healthy lungs to ﬁbrotic lungs in the case of IPF, as shown in
the ﬁbrosis spectrum (Supplementary Fig. 12). The mildly increased
levels of PET-tracer accumulation in the lungs of the two healthy
mid-40s female volunteers (HV-2 and HV-4, ~ 3σ from baseline-20
SUVmean) suggests that αvβ6 levels increase with age. Interestingly,
the high end of [18F]FP-R01-MG-F2’s ﬁbrosis spectrum from the
healthy volunteers group (7σ from baseline-20 SUVmean) was
observed in a 48-year-old asymptomatic male (HV-1), who is a
long-term bird-owner with a history of chronic second-hand-smoke
and wood-dust exposure35,51. Although his low-dose chest CT
showed relatively normal lungs, [18F]FP-R01-MG-F2 levels in HV-1
(SUVmean ~ 1.4) were higher and overlapped with IPF-3’s SUV
metrics in the lower range of the ﬁbrosis spectrum (SUVmean ~ 1.1,
Supplementary Table 13).
The possibility that [18F]FP-R01-MG-F2 can monitor dynamic
changes in ﬁbrosis was also suggested by patient IPF-4’s suc-
cessfully transplanted left lung, where tracer uptake levels were
similar to levels recorded in lungs from healthy volunteers
(Fig. 7). αvβ6 plays a key role in wound healing, and accumulation
of the PET tracer is expected if the administration of [18F]FP-
R01-MG-F2 had occurred during active tissue remodeling53.
Interestingly, [18F]FP-R01-MG-F2 did not accumulate at the
bronchial anastomosis site, suggesting the wound-healing process
was complete 2-year post-transplant when the PET study was
conducted.
The current pilot study for IPF was limited by the lack of
histological data for patient-matched tissues. Although the
expression of αvβ6 in IPF has been immunohistologically con-
ﬁrmed in multiple previous studies, patient-matched IHC studies
may provide additional insight into correlation between PET
tracer uptake and severity of disease2,28. Finally, our study does
not contain enough clinical data to determine statistical correla-
tion to other metrics used in IPF such as pulmonary
function tests.
The accumulation of the knottin PET tracers occurred in the
pituitary gland of all study subjects (where the PET scan included
the brain, n= 11); this was an unexpected ﬁnding in our study.
Although accumulation of our tracers did not occur in the other
major regions of the normal human brain, we observed rapid and
sustained uptake of our αvβ6 probes in the pituitary region
throughout the duration of the study (SUVmean ~ 4 at 1 h p.i.). A
review of the literature indicated that several integrins are
expressed in the normal pituitary gland, and that the expression
pattern of integrins expressed in the pituitary changes with the
occurrence of adenomas, which represent about 10–15% of all
intracranial neoplasms54–56. Most of the studies that surveyed
integrin expression in the pituitary were conducted many years
earlier with a limited repertoire of antibodies for IHC, and before
most investigators ever looked for the expression of the β6
integrin subunit in the pituitary gland. Therefore, there are sev-
eral reports that provide a list of integrin subunits that were
investigated at that time except for the β6 subunit. We were not
able to ﬁnd any current studies which conﬁrmed, either at the
message or protein level, the expression the β6 subunit in the
pituitary. Moreover, there are several conﬂicting reports about the
expression of the αv subunit in the healthy and diseased pitui-
tary54,57. A parallel line of potentially related research has focused
on the expression of TGF-β1 expression in the pituitary gland.
Local TGF-β1 expression has been conﬁrmed in both normal and
cancerous pituitary tissues55,58,59. The reason that this is impor-
tant for our studies is that expression of TGF-β1 is often asso-
ciated with the expression of its activator, αvβ629,60. Accumulation
of our probe may have provided evidence for the expression of
αvβ6 in the human pituitary. Although the anterior portion of
pituitary gland remains outside of the blood brain barrier, our
studies show that it is possible to target a 4 kDa peptide probe
to the pituitary gland, which may allow the detection of
adenomas or prolactinomas by developing probes that target
cell surface proteins, such as other integrins that are speciﬁc
for those diseases. Moreover, because of the sustained uptake of
the knottin PET tracers in the pituitary, our studies suggest
that it may be possible to exploit knottins, such as R01-MG, for
delivery of therapeutic activities to that region of the brain.
In conclusion, we have addressed several unmet clinical needs
by developing cystine knot PET tracers that effectively detect
multiple cancers in different regions of the body, as well as
ﬁbrotic changes in the lungs in IPF patients. In pancreatic, cer-
vical and lung cancer, and in IPF, the knottin PET tracers
demonstrated rapid and sustained accumulation in diseased tis-
sues with relatively low background uptake in healthy organs or
regions of the body prone to different cancers or ﬁbrosis (lung
and liver). These results suggest that the R01-MG based PET
tracers will have broad clinical application in detecting/diagnos-
ing multiple indications, monitoring the efﬁcacy of multiple
therapeutics, as well as in staging both cancer and pulmonary
ﬁbrosis. The results from these pilot clinical studies encourage
comprehensive evaluation of these αvβ6 cystine knot PET tracer
across a broad range of disease states and applications in different
patient populations.
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Methods
Materials, cell lines, and reagents. BxPC-3 human pancreatic cancer cells were
obtained from American Type Culture Collection (ATCC) and grown in RPMI
1640 media (ATCC). A431 epidermoid cancer cells, human embryonic kidney
293T cells (293T) cells were obtained from frozen lab stocks and grown in DMEM
supplemented with 10% FBS and penicillin/streptomycin (Invitrogen). Recombi-
nant human integrins αvβ6 was purchased from R&D Systems. Yeast growth
materials (SD-CAA, SG-CAA, SD-CAA agar plates, YPD) were purchased from
Teknova. All other chemicals were obtained from Fisher Scientiﬁc unless otherwise
speciﬁed. Integrin binding buffer (IBB) is composed of 25 mM Tris pH 7.4,
150 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 1 mM MnCl2, and 0.1% bovine serum
albumin (BSA).
Site directed evolution. The open reading frames encoding cystine knot peptides
were generated by overlap-extension PCR using yeast-optimized codons deﬁned by
Lasergene (DNASTAR.com). The position that was randomized, as denoted by the
letter x in Supplementary Fig. 1, was constructed with the NNB degenerate codon
sequence. PCR products were ampliﬁed using primers with overlap to the pCT
yeast display plasmid, which were upstream or downstream of the NheI and
BamHI restriction sites, respectively. For each library, ~40 µg of DNA insert and
4 µg of linearized pCT vector were electroporated into the S. cerevisiae strain
EBY100 by homologous recombination. Electroporation was performed using
cuvettes with a 2 mm gap. The electroporator was set to exponential decay mode,
540mV and 25 µf.
The library was incubated and screened at room temperature for 2 h in 1 nM of
recombinant integrin αvβ6 in IBB31. Next, a 1:250 dilution of chicken anti-cMyc
IgY antibody (AB_2535826, Cat # A-21281, ThermoFisher) was added for 1 h at
4 °C. The cells were washed with ice-cold IBB and incubated with a 1:25 dilution of
ﬂuorescein-conjugated anti-human αv integrin antibody (Clone NK1-M9, Cat #
327908, Biolegend) and a 1:100 dilution of Alexa 555-conjugated goat anti-chicken
IgG secondary antibody (AB_2535858, Cat # A-21427, ThermoFisher) for 0.5 h at
4 °C. Cells were washed in IBB and αvβ6 integrin binders were isolated using a
Becton Dickinson FACS Aria III instrument. A diagonal sort gate was used to
isolate yeast cells with enhanced integrin binding (FITC ﬂuorescence) for a given
protein expression level (Alexa 555 ﬂuorescence). Plasmid DNA was recovered by
Zymoprep (Zymo Research), ampliﬁed in Max Efﬁciency DH5α E. coli cells
(Invitrogen) and sequenced.
Determination of equilibrium dissociation constants. Various concentrations
(100 nM to 300 pM) of recombinant integrin αvβ6 were incubated with 105 yeast
cells expressing R01, R01-MG, R01-MR, or R01-MW in the presence of 106 un-
induced yeast cells. Prior to ﬂow cytometry and analysis, yeast cells were processed,
stained, and washed as described above in the section called Library Synthesis and
Screening. Using two color ﬂow cytometry, the binding of knottin (FITC) to
integrin αvβ6 was normalized to expression level (Alexa 555) prior to determination
of equilibrium dissociation constants (KD). The normalized binding was plotted
against the log of the concentration of recombinant integrin αvβ6. The KD was
determined by nonlinear regression analysis using Kaleidagraph (Synergy
Software).
Determination of IC50s of knottin derivatives. Various concentrations of syn-
thetic knottin peptide R01-MG and its derivatives were incubated with 10 nM
integrin αvβ6 at room temperature overnight. In order to determine the half-
maximal inhibitory concentration, the ligands, R01-MG, DOTA-R01-MG,
NODOGA-R01-MG, [19F]FP-R01-MG-F1 and [19F]FP-R01-MG-F2 were allowed
to compete with 105 induced yeast cells (in the presence of 106 un-induced carrier
yeast cells) surface-displaying R01-MG for binding to recombinant integrin αvβ6. A
ten-fold molar excess of test ligand, relative to the moles of yeast surface displayed
R01-MG, was provided to the system (~50,000 R01-MG/yeast cell).
Peptide synthesis and folding. Precursor peptide R01-MG was synthesized on a
CS Bio CS336 instrument via 9-ﬂuorenylmethoxycarbonyl (Fmoc)-based solid
phase peptide synthesis methods, and a Rink amide resin (CS Bio). Fmoc-protected
amino acids were purchased from CS Bio. Fmoc groups were removed with 20%
piperidine in DMF. Amino-acid coupling was performed using HOBt/diisopro-
pylcarbodiimide (DIC) chemistry in DMF. Side-chain deprotection and resin
cleavage was achieved by addition of a 94:2.5:2.5:1 (vv−1) mixture of triﬂuoroacetic
acid (TFA)/trimethylsilane/ethanedithiol/water for 2 h at room temperature. The
crude peptides were precipitated with cold, anhydrous diethyl ether and puriﬁed to
>95% purity by semi-preparative reversed-phase HPLC using a Dionex Ultimate
3000 HPLC system and a Vydac 218TP1010 C18 column. Linear gradients of 90%
acetonitrile in water containing 0.1% (v v−1) TFA were used for all peptide pur-
iﬁcations, which were monitored at an absorbance of 220 nm. Peptide purity was
analyzed by analytical reversed-phase HPLC using either a 214TP C4 5μ or Phe-
nomenex Aeris C18 column. Molecular masses were conﬁrmed by matrix-assisted
laser desorption/ionization-mass spectrometry (MALDI-MS; ABI 5800, Supple-
mentary Table 1).
Precursor peptide folding reactions were performed by gently rocking peptides
for 12–20 h in a 0.1 M ammonium bicarbonate, pH9 solution containing 2.5 mM
reduced glutathione, 20% dimethlysulfoxide (v v−1), 20% isopropanol (vv−1), and
20% 0.8 M guanidinium hydrochloride. The ﬁnal oxidized (folded) precursor
product was puriﬁed by semi-preparative reversed-phase HPLC as described above.
Following puriﬁcation, folded peptides were lyophilized and stored at room
temperature until used. Puriﬁed peptides were dissolved in water, and
concentrations were determined by amino acid analysis (Jay Gambee AAA Service
Laboratory, Damascus, OR). Peptide purity and molecular mass were conﬁrmed by
analytical reversed-phase HPLC and MADLI-MS. The CGMP precursor peptide
R01-MG was made, using a similar protocol, by CS Bio (Menlo Park CA).
DOTA or NODAGA conjugation. Brieﬂy, 1–2 mg of peptides were conjugated to
~2 mg DOTA-NHS (Macrocyclics, Plano TX) or NODAGA-NHS (Chematech,
Dijon France) in 500 μL DMF containing 2 μL DIPEA at room temperature for up
to 1 h. Chelator-peptide conjugates were acidiﬁed in solvent A puriﬁed by semi-
preparative reverse phase HPLC as described above.
64Cu radiolabeling. Approximately 10 μg of peptide were combined with ~2 mCi
64CuCl2 in ~500 μL 100mM sodium acetate buffer pH5.5 at 37 °C with gentle
shaking at 250 rpm for at least 1 h prior to puriﬁcation by PD-10 column. Twelve
500 μL fractions were collected from the column. The active fraction (typically 6
and 7) was subsequently used for in vivo studies.
68Ga radiolabeling. 68GaCl3 was eluted from a 68Ge/68Ga generator with 0.1 N
HCl. [68Ga]NODAGA-R01-MG was prepared by adding ~2 mCi (~75 MBq)
68GaCl3 to ~10–20 μg NODAGA-R01-MG in 500 μl 0.1 N NH4OAc (pH 4.5). The
mixture was incubated in a shaker at 250 rpm for 15 min at 40 °C. The mixture was
puriﬁed by PD-10 column as described above in 64Cu radiolabeling.
Radiosynthesis and puriﬁcation of [18F]FP-R01-MG-F2. The radiosynthesis of
[18F]-4-nitrohenyl-2-ﬂuoropropanoate ester ([18F]NPE) was accomplished via
nucleophilic 18F ﬂuorination of methyl 2-bromopropionate, hydrolysis, and
esteriﬁcation in an automated radiosynthesizer (TRACERlab FX N PRO; GE
Healthcare). Subsequently, [18F]NPE was puriﬁed on a reverse phase HPLC
column (Luna C18 250 × 10 mm, 5 μm, Phenomenex) with gradient conditions
(A: H2O+ 0.1% TFA, B: CH3CN+ 0.1% TFA; 0-2 min 5% B, 2-32 min 5–65% B,
5.0 mLmin−1). The conjugation between pure [18F]NPE and the cystine knot
peptide, R01-MG was performed in a semi-automated customized radiosynthesis
module to yield [18F]FP-R01-MG. The crude product was puriﬁed on a reverse
phase HPLC column (Gemini C18 250 × 10mm, 5 μm, Phenomenex) with gra-
dient conditions (A: H2O+ 0.1% TFA, B: CH3CN+ 0.1% TFA; 0–2 min 10% B,
2–10 min 10–20% B, 10–20 min 20–23% B, 20–65 min 23–30% B, 5.0 mLmin−1).
As described above, both fractions of [18F]FP-R01-MG, F1 and F2, were present.
However, it was hard to achieve pure [18F]FP-R01-MG-F1 since it was coeluted
with a radioactive impurity. Therefore, it was excluded from further development.
At the same time, [18F]FP-R01-MG-F2 was consistently obtained >90% purity.
Tumor models. We have complied with all relevant ethical regulations for animal
testing and research. Animal procedures were performed with approval from the
Stanford University Administrative Panels on Laboratory Animal Care (APLAC,
protocol #9536). Female athymic nude mice, 4–6 weeks old (Charles River), were
subcutaneously shoulder-injected with 107 cells suspended in 100 µL PBS. Mice
were used for imaging and biodistribution studies when xenografted tumors grew
to a diameter of ~1 cm.
Static small animal PET imaging. Tumor-bearing Nu/Nu female mice (n= 3 for
each probe) were anesthetized using 2% isoﬂurane in oxygen and injected with
~100 µCi (~0.15 nmol) of the tracers described above via the tail vein. Five-minute
static PET scans were acquired on an Inveon PET-CT or Inveon D-PET scanner
(Siemens Healthcare, Malvern PA). Images were reconstructed by a two-
dimensional ordered expectation maximum subset algorithm and calibrated as
described below. ROIs were drawn over the tumor on decay-corrected whole-body
images using Inveon Research Workplace (IRW) software (Siemens) or ASIPro
VM software (Siemens). ROIs were converted to counts g−1 min−1, and %ID g−1
values were determined assuming a tissue density of 1 g ml−1.
Calibration of small animal PET. Scanner activity calibration was performed to
map between PET image units and units of radioactivity concentration. A pre-
weighed 50-mL centrifuge tube was ﬁlled with distilled water and 64CuCl2
(∼9.3 MBq [∼250 μCi] as determined by the dose calibrator) was used to simulate
the whole body of the mouse. This tube was weighed, centered in the scanner
aperture, and imaged for a 30-min static image, single bed position. From the
sample weight and assuming a density of 1 g ml−1, the activity concentration in the
bottle was calculated in units of μCi mL−1. Eight planes were acquired in the
coronal section. A rectangular region of interest (ROI) (counts/pixel/s) was drawn
on the middle of eight coronal planes. Using these data, a calibration factor (C) was
obtained by dividing the known radioactivity in the cylinder (μCi mL−1) by the
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image ROI. This calibration factor was determined periodically and did not vary
signiﬁcantly with time.
Dynamic small animal PET and PET/CT imaging. Dynamic scans were acquired
over ~2 h p.i. Image acquisition was initiated 15 seconds prior to tracer injection
and proceeded for 115.1 min p.i. The acquired data were then sorted into 0.5-mm
sinogram bins and 26 time frames for image reconstruction (4 × 15 s, 1 × 37.5 s, 4 ×
60 s, 11 × 300 s and 5 × 600 s), which was done by iterative reconstruction using the
following parameters: 3D ordered-subsets expectation maximization (3D-OSEM)
followed by fast maximum a posteriori (fastMAP); MAP OSEM iterations: 2; MAP
subsets: 16; MAP iterations: 18. ROI analysis (IRW) was performed on the tumor
and the major organs (heart, liver, kidneys, bladder, and muscle) seen on the
dynamic PET scan images. The count densities were averaged for all volumes of
interest at each timepoint to obtain a time versus radioactivity curve (TAC). Tumor
TACs were normalized to injected dose, measured by a CRC-15 PET dose cali-
brator (Capintec, Inc.), and expressed as percentage injected dose per gram of
tissue (%ID g−1), assuming 1 g ml−1.
Pre-clinical radiation dosimetry. Non-decay-corrected uptake (%ID g−1) values
from the dynamic PET study (above) were converted to %ID organ−1 and then
subjected to an animal-to-human biokinetic extrapolation using the percent kg g−1
method where (%ID organ)human= [(%ID g−1)animal × (kgTBweight)animal × gorgan
(kgTBweight)human−1]. The animal whole body weight was 34 g and the weights of
the human organs were derived from a 73 kg male and 58 kg female in Organ level
Internal Dose Assessment (OLINDA) software; source organ residence times were
calculated using a bi-exponential model OLINDA61. The projected human doses
were then computed for human phantoms using the source organ residence times.
In vitro and in vivo stability. Aliquots of [18F]FP-R01-MG-F2 were incubated in
an equal volume of AB Human Serum (Invitrogen, 34005100) for 2 h at 37 °C.
Samples were acidiﬁed with TFA and centrifuged at 18,000 g for 3 min to remove
precipitants. For in vivo stability, mouse urine was collected with a syringe
immediately after euthanasia. Typically, ~100 μL of urine was released by the
bladder as it relaxed when the mice died; urine pooled at the genitals and was
stabilized by surface tension. All samples were analyzed by radio-HPLC on a
Dionex C4 column.
Biodistribution analysis. Anesthetized nude mice bearing xenograft tumors were
injected with ~100 µCi (~0.15 nmol) of the radio peptides described above via the
tail vein, and euthanized after 1 h, 2 h, 4 h and or 24 h for the studies involving the
[64Cu]DOTA-labeled peptides, and at 0.5 h and 2 h for studies involving [18F]FP-
and [68Ga]-NODAGA labeled peptides. Tissues were removed, weighed and
measured by scintillation counting62. Radiotracer uptake in tissues was reported as
%ID g−1 and represents the mean ± standard deviation of experiments performed
on three or more mice.
Synthesis and characterization of [19F]FP-R01-MG-F2. In preparation for
clinical development, the cold ﬂuorine-19 lead compound, [19F]FP-R01-MG, was
chemically synthesized, and characterized by RP-HPLC, MALDI-MS, x-ray crys-
tallography, and NMR spectroscopy.
The following describes part 1 of the [19F]FP-R01-MG-F2 Synthesis, the
synthesis of the [19F] Nitrophenyl Ester (NPE). 2-Fluoropropionic Acid (FPA) was
mixed with 1M NaOH in a 1:1 ratio and allowed to react at 95 °C for 10 min. The
reaction mixture was transferred to a round bottom ﬂask and two volumes of
acetonitrile was added to the mixture for azeotropic distillation at 30 °C on a
Rotary Evaporator. The sodium 2-ﬂuoropropionate (FP-Na+) product appeared to
be a white ﬂaky powder with a molecular weight of 130.15 g n−1. Its mass and
structure were veriﬁed by ESI-MS and NMR, respectively.
Next, sodium 2-ﬂuoropropionate (solid) was mixed with 328 mM bis(4-
nitrophenyl) carbonate (NPC) in acetonitrile in a 1:2 to 1:7 molar ratio. The round
bottom ﬂask was placed in 90–110 °C oil bath for 20–30 min. The resulting
product, 2-ﬂuoro nitrophenyl propanoate referred to as the nitrophenyl ester ([19F]
NPE) compound was puriﬁed by semi-preparative RP-HPLC using a Phenomenex
Gemini C18 column. A 90% acetonitrile, 0.1% triﬂuoroacetic acid (TFA, solvent B)
gradient was used. The solution containing puriﬁed [19F]NPE was next diluted in a
1:1 (vv−1) ratio with solvent A (99.9% H2O, 0.1% TFA) and loaded onto a Waters
Sepak C18 column, which was rinsed three times with solvent A. The puriﬁed
product, [19F]NPE was eluted from the Sepak into a 20 mL glass storage bottle
using 2 mL diethyl ether. The ether was evaporated on a hot plate (80–90%) in the
presence of an air stream, which resulted in dry [19F]NPE as a white crystal ﬁlm.
The following describes part 2 of the [19F]FP-R01-MG-F2 Synthesis, coupling of
Precursor R01-MG to NPE. Both the precursor R01-MG and NPE were
resuspended in anhydrous DMF and mixed in a 1:1 molar ratio in the presence of
0.5% (v v−1) DIEA. Coupling of the ﬂuoropropyl group to the precursor occurs on
the sole amine functionality present on the N-terminus of R01-MG and nowhere
else on the peptide. The reaction was allowed to proceed for up to 1 h. The reaction
was terminated by addition of 9 volumes of HPLC buffer A (99.9% H20 and 0.1%
TFA). RP-HPLC indicated two products, fraction 1 ([19F]FP-R01-MG-F1) and
fraction 2 ([19F]FP-R01-MG-F2), separated by ~1 minute. Each product was
separately puriﬁed to homogeneity by RP-HPLC. MALDI-MS and NMR revealed
identical spectra and masses of 3906 Da for both [19F]FP-R01-MG-F1 and [19F]FP-
R01-MG-F2 (Supplementary Table 1).
NMR spectroscopy. 2D 1H-1H NOESY and 1H-1H TOCSY NMR spectroscopy
data were acquired on 1.0 mM R01-MG and 18F-ﬂuoropropyl-R01-MG ([18F]FP-
R01-MG) cystine knot peptides in 20 mM potassium phosphate, pH 6.0 at
300 K63,64,65. After HPLC fractionization, peptide preparations were lyophilized.
Aqueous peptide solutions with 5% D2O including 0.05 wt% 3-(trimethylsilyl)
propionic-2,2,3,3-d4 acid (Sigma-Aldrich 450510) of R01-MG and [18F]FP-R01-
MG were prepared, neutralized, and pH adjusted to pH 6.0 with 3 μl 1 N NaOH
(1:10 diluted Amresco E584) to a ﬁnal volume of 200 μl into 3 mm NMR tubes
(C-S-3-HT-7, Norrell). 2D 1H-1H NMR spectroscopy data were recorded using
phase-sensitive homonuclear 2D 1H-1H NOESY with presaturation and homo-
nuclear 2D 1H-1H TOCSY with Hartman-Hahn transfer using MLEV17 spinlock
sequence with presaturation at 128 scans, 512 indirect complex data point,
d1= 2.5 s, 1 H pulse 7.6μs, power level of shaped pulse 25.55db, mixing time
d8= 80 ms (in the case of NOESY also 120, 250, 300 ms to assess NOE spin dif-
fusion)66,67 and an experimental time of about 24 h at 300 K at an Avance II 600-
MHz spectrometer ﬁtted with a cryogenic probe operating with TOPSPIN 3.0
(Bruker BioSpin GmbH). All spectra were Fourier transformed, phased, baseline
corrected, and referenced to TSP (δ 0.00 ppm) using NMRPipe version X68.
Solutions of R01-MG before and after 18F-ﬂuoropropyl derivatization showed
similar dispersion of the amide ﬁnger print region between 8 and 10 ppm 1H
chemical shift indicative of an intact cystine knot fold. 2D NMR spectra were
overlaid, analyzed, assigned, and integrated using NMRView version 5.2.269–72.
2D 1H-1H NOESY spectral peak lists were calibrated at a reference distance of
5.2 Å and a tolerance spectral resolution limit for 1H-1H NOE resonance set at
0.03 ppm. 2D 1H-1H NOESY spectral peak lists were converted into 233 upper
limit distance constraints for automated structure calculation using CYANA ver-
sion 3.9773. In addition, disulﬁde bond restraints were generated for the three
disulﬁde bonds. 2, 90, 86, 45, and 97 intra-residue, sequential, short-range, med-
ium-range, and long-range upper limit distance constraints, respectively, were
observed. A structural ensemble of 100 different structural conformers based on
upper limit distance constraints using simulated annealing and torsion angle
dynamics protocol were calculated and the top 20 lowest energy structures were
archived. NMR structural ensembles of R01-MG wildtype and [18F]FP-R01-MG
FP-labeled cystine knot recognizing the integrin αvβ6 cancer recognition site were
deposited in the protein data bank with coordinates (2N8B.pdb) and (2N8C.pdb).
Crystallization of [19F]FP-R01-MG-F2. Initial crystallization conditions were
screened with four commercial screening kits: (1) Crystal Screen HT (CSHT), 2)
SaltRx HT, 3) PEG/Ion HT, and 4) Index HT by Hampton Research (Aliso Viejo,
CA). Screens were performed with 96-well Intelliplates on a Crystal Gryphon Flex
Instrument (Art Robbins Instruments, ARI, Sunnyvale, CA). Brieﬂy, 0.3 μl or 0.6 μl
of [19F]FP-R01-F2 (15 mgml−1) were added to 0.3 μl of screening solution. Images
were obtained using a CrysCam Digital Microscope System (ARI). At ~24 h,
crystals were observed in SCHT wells B7, C3 and D4, which contained 30%, 20%
and 20% v v−1 2-propanol, respectively. (Supplementary Fig. 2).
Summary of Buffer Compositions: B7: 0.2 M Ammonium acetate, 0.1 M TRIS
hydrochloride pH 8.5, 30% vv−1 2-propanol
C3: 0.2 M Sodium citrate tribasic dehydrate, 0.1 M HEPES sodium pH 7.5, 20%
v v−1 2-propanol
D4: 0.1 M Sodium citrate tribasic dehydrate pH 5.6, 20% v v−1 2-propanol, 20%
w v−1 PEG 4000
Noting the three isopropanol-containing CSHT solutions, a 24-way
optimization grid was set-up with a Scorpion robotic instrument (ARI). The CSHT
D4-based wells contained 0.1 M Sodium citrate pH 5.6. The variables included
16–26% PEG 4 K (x-axis) and 15–30% 2-propanol (y-axis). Crystals were observed
throughout the grid (Fig. 6b). Next, the concentration of [19F]FP-R01-F2 was
decreased to 10 mgml−1 to produce discrete high-quality crystals (50–200 μm),
which grew slowly after several days in a well that contained 0.1 M sodium citrate
tribasic dehydrate pH 5.6, 25% v v−1 2-propanol and 18% w v−1 PEG 4000.
Crystals were preserved in a universal cryo-protectant, mounted on magnetic ALS
CrystalCap/Cryoloop pins (Hampton Research) and stored in liquid nitrogen.
X-ray data collection of [19FN]FP-R01-MG-F2. X-ray diffraction experiments
were performed at the MBC Beamline 4.2.2 of the Advanced Light Source using the
RDI-8 m CMOS detector74. Crystals were tested for diffraction using a Superbend
magnet source coupled to a Rosenbaum-Rock Si(111) sagitally focused mono-
chromator with an energy range of 5500–16,000 eV. An ACTOR robot (Rigaku)
was used to load frozen crystals into position on the beamline. A number of CSHT-
optimized D4 crystals (50–200 μm) were screened and produced high-quality
diffraction data beyond 1.0 Å resolution. For each crystal, 180 degrees of data were
collected in shutterless mode with 0.1 degree frames at an energy of 1.00 Å and a
temperature of 100 K; if necessary, a second dataset was collected on the same
crystal at 50% attenuation to record overloaded reﬂections from the ﬁrst pass.
Datasets from individual crystals were indexed, integrated, scaled, and merged in
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the XDS/XSCALE package75. The scaled reﬂections were converted to mtz format
with Free R ﬂags in the CCP4 package76,77.
X-ray structure determination of [19F]FP-R01-MG-F2. In order to solve the
structure, we used a high-quality dataset obtained from a crystal that diffracted to
1.05 Å (Table 2). The phases for [19F]FP-R01-MG-F2 were solved using a molecular
replacement search model made from the NMR structure of the parent peptide
scaffold Momordica Cochinchinensis Trypsin Inhibitor II (MCoTI-II, 2IT8.pdb and
2N8B.pdb) subsequently engineered by our group to develop the precursor peptide
R01-MG. MCoTI-II and R01-MG share ~60% sequence identity; they are different
in their active Loop-1 (Supplementary Fig. 2).
The initial search model was generated by deletion of the active 2000-1 and
conversion of all other non-identical (non-loop) residues to serine. Molecular
replacement program PHASER, which is a part of the CCP4 crystallography
program suite, was used to search two molecules in the asymmetric unit
(ASU)76,78. An initial solution with the search model was obtained in P212121
space group.
The model-building program ARP/wARP was used to automatically construct
more than 90% of the model in the ASU79. A complete model was obtained by
further cycles of manual reﬁnement and loop building in Refmac5 (CCP4 suite)
and COOT80. Once all the amino-acid residues were ﬁtted to the electron density
map, the N-terminus ﬂuropropyl group was manually determined by using the
ligand generating tools in the CCP4 suite and COOT. Further reﬁnement cycles led
to a ﬁnal molecule, 6CDX.pdb, with an R-Factor (Rwork) of 0.18 and a resolution of
1.05 Å.
Toxicology study on the reference standard [19F]FP-R01-MG-F2. A toxicity
study of [19F]FP-R01-MG-F2 peptide in Sprague Dawley rats was conducted by
Sobran Inc, Bioscience Division, Sobran Rangos Animal Facility (Baltimore, MD).
A complete report called “14-Day Single Intravenous Dose Toxicity Study of [19F]
FP-R01-MG-F2 in Sprague Dawley Rats” was dated February 24, 2015 (Supple-
mentary Information).
Brieﬂy, twenty male and female rats (10 sex−1 group−1, 5 sex−1 sacriﬁce
timepoint−1) were assigned to a dose group and a vehicle control group and
administered [19F]FP-R01-MG-F2 peptide tracer intravenously via the tail vein at 0
(vehicle only) and 1.10 mg kg−1 (0.22 mgmL−1) as a single dose on Study Day 1.
Groups of 5 animals sex−1 were sacriﬁced on Study Days 3 (48 h) and 15 for
evaluation of clinical pathology and organ toxicity. The dose of [19F]FP-R01-MG-
F2 used for these toxicity studies was more than 250× the maximum estimated dose
of the [18F]FP-R01-MG-F2 tracer that may be injected into a human subject. The
animals were monitored prior to the administration of the test article, [19F]FP-R01-
MG-F2, and up to 14 days following the administration of the test article.
Parameters evaluated for test article effect included survival, clinical observations,
body weight, body weight gain, clinical pathology, gross pathology, organ weights,
and microscopic pathology.
Clinical inclusion and exclusion criteria (Stanford). The following studies were
approved by Stanford’s Institutional Review Board and Scientiﬁc Review Com-
mittee. The clinical studies were conducted in the Division of Nuclear
Medicine and Molecular Imaging at Stanford University Nuclear Medicine Clinic
under US-FDA eIND 126379 (S.S. Gambhir), and ClinicalTrials.gov Identiﬁer
NCT02683824.
Healthy volunteer inclusion criteria. Volunteers met all of the following inclusion
criteria and were considered eligible for participation in this study.
● 18-year old or older at the time of radiotracer administration
● No known medical problems and completed a full medical exam within
6 months of the study
● Understood and voluntarily signed an Informed Consent after its contents
were fully explained
Pancreatic cancer patient inclusion criteria. Cancer patients met all of the fol-
lowing inclusion criteria and were considered eligible for participation in this
study.
● 18-year old or older at the time of radiotracer administration
● Provided written Informed Consent
● Diagnosed with pancreatic cancer and scheduled to undergo surgery
● Able to remain still for duration of each imaging procedure (about 1 h)
IPF patient inclusion criteria.
● 18-year old or older at the time of radiotracer administration
● Patient provided written Informed Consent
● Patient diagnosed with IPF by a pulmonologist according to ATS guidelines
● Patient has high-resolution CT with usual interstitial pneumonia (UIP)
pattern
● Patient has PFT’s within the last 12 months with
FVC < 85% predicted
DLCO < 65% predicted
FEV1/FCV ratio > 0.7
● Patient is able to comply with study procedure
Scanning Option A (60 min dynamic PET scan and two 20 min static PET
scan) OR
Scanning Option B (two 10 min static PET scans)
Healthy volunteer exclusion criteria. If volunteers met any of the following
exclusion criteria, they were considered ineligible for participation in this
study.
Less than 18-year old at the time of radiotracer administration
Pregnant or nursing
Pancreatic cancer patient exclusion criteria. If cancer patients met any of the
following exclusion criteria, they were considered ineligible for participation in this
study.
Less than 18-year old at the time of radiotracer administration
Pregnant or nursing
Contraindications for PET/CT
Unable complete a PET/CT scan
Unable to comply with the study procedures
Serious uncontrolled concurrent medical illness that would limit compliance
with study requirements
Eastern Cooperative Oncology Group Performance Status (ECOG PS) > 2
IPF patient exclusion criteria.
Patients with serious uncontrolled concurrent medical illness that would limit
compliance with study requirements.
Patient has history of any clinically signiﬁcant lung disease other than IPF as
determined by pulmonologist.
Patient has had a lung infection of any kind in the last 3 months.
Healthy volunteer, Panc CA* and IPF patient** (Stanford).
1. Participant was asked to drink 1-2 glasses oher arrival at the clini/her arrival
at the clinic.
2. Participants was consented by the responsible physician.
3. Female participants had an early pregnancy test (EPT) to rule out
pregnancy.
4. Participants was asked to urinate prior to start of study and instructed to
collect a urine sample.
5. Participant was weighed and measured in height.
6. Participant had an IV line placed in an arm vein for tracer administration.
7. Participant had a second IV line placed in an arm vein for blood sampling.
8. A blood sample was taken 5 min prior to the injection of the tracer and used
for baseline chemistry and hematology laboratory testing.
9. [18F]FP-R01-MG-F2 was formulated in a sterile and pyrogen-free isotonic
solution and was administered in a single slow IV injection. The line was
ﬂushed with at least 10 ml normal saline after injection.
10. Blood samples for blood time activity measurements were taken at 1, 3, 5,
and 10 min after tracer administration and then at 30-minute intervals for
up to 3 h after tracer injection. The counts in whole blood and plasma were
measured by gamma counter (Perkin Elmer Wizard 1470). All blood counts
were decay corrected to the time of tracer injection.
11. A small low activity calibration source of known activity of 18F was placed in
the ﬁeld of view in each image collected.
12. *For pancreatic cancer, dynamic PET scans were acquired for approximately
45 min after intravenous administration of the radiopharmaceutical [18F]
FP-R01-MG-F2. The scan was performed over the abdominal region to
include the pancreas. Attenuation correction was employed via CT (120 kV,
10 mA). For the pancreatic cancer patient, an [18F]-FDG PET scan of the
abdominal region was performed on a different day prior to the [18F]FP-
R01-MG-F2 study.
13. **For the IPF cohort (option A), dynamic PET scans were acquired for
approximately 60 min after intravenous administration of the radio-
pharmaceutical [18F]FP-R01-MG-F2. The scan was performed over the
chest region. Attenuation correction was employed via CT (120 kV, 10 mA).
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14. Static total-body (vertex-to-toe) PET/CT scans were acquired at 60 min and
120 min post injection. CT was performed at 120 kV; it was dose-modulated
based on body habitus with current ranging from 10-105 mA for the 60-
minute scan. Attenuation correction was also used with CT for the 120-
minute scan (120 kV, 10 mA).
15. Blood pressure, temperature, heart rate and pulse oximetry measurements
were taken before injection (baseline) and at 5, 10, 15, 60, and 120 min after
[18F]FP-R01-MG-F2 injection.
16. EKG monitoring was performed before [18F]FP-R01-MG-F2 injection and
then at 15 min intervals for up to 3 h after [18F]FP-R01-MG-F2 injection.
EKG data was analyzed to assess changes in overall rhythm of the heart.
17. On the day of the study, participants were asked to void frequently to reduce
radiation exposure. Urine samples were collected at prior to tracer
administration (baseline), prior to the static PE scans, at the end of the
study day 1, and at the follow up visits 1 day and 7 days after tracer
administration. Urine was analyzed by gamma counting.
18. Participants were given a copy of the informed consent form that they
signed and were dismissed.
19. Adverse drug events were recorded for 3 h after [18F]FP-R01-MG-F2
injection and at 24 h and 1 week after [18F]FP-R01-MG-F2 injection.
20. Participants were asked to return to the clinic the next day and at 7 days
post injection of tracer, for blood sample collection (for blood chemistry and
hematology) and also for monitoring of vital signs.
Administration of [18F]FP-R01-MG-F2 in healthy volunteers. A bolus of [18F]
FP-R01-MG-F2 was administered intravenously to ﬁve healthy male and female
adult volunteers; the mean ± SD injected dose of [18F]FP-R01-MG-F2 was 7.5 ±
1.3 mCi and the mean injected mass was 12.5 ± 4.0 μg or 0.18 ± 0.06 μg kg−1
(Supplementary Table 4). No adverse effects were reported by volunteers or noticed
by physicians and staff for up to 7 days after injection of [18F]FP-R01-MG-F2.
Oxygen levels, vital signs and electrocardiography (ECG) readings stayed within
normal range from pre-injection to 24 h and 7 days after administration of the PET
tracer (Supplementary Tables 5 and 6).
[18F]FP-R01-MG-F2 vs. [18F]FDG in pancreatic CA. Dosages of 10.2 mCi [18F]
FDG and 5.1 mCi [18F]FP-R01-MG-F2 were separately administered on different
days to a 61-year-old woman with pancreatic cancer scheduled for surgical
resection (Supplementary Table 10).
[18F]FP-R01-MG-F2 in IPF lungs. One female and ﬁve male study subjects, 72.5 ±
1 y.o., who were diagnosed with IPF according to international consensus diag-
nostic criteria of either a chest CT demonstrating a deﬁnite UIP pattern or lung
tissue biopsy with a histopathologic UIP pattern, were administered 5–10 mCi of
[18F]FP-R01-MG-F21. One male study subject experienced dyspnea, elevated heart
rate, coughing and shivering during the study. The female study subject reported
shortness of breath and nausea after 48 h. Upon review by our nuclear medicine
physicians and pulmonary physicians, it was determined that these potentially
adverse reactions were not likely study-related, but rather a result of the underlying
disease.
Analysis of radiotracer in study subject’s blood. Blood samples for time-activity
measurements were obtained at 1, 3, 5, and 10 min after tracer injection and then at
30-min intervals for up to 3 h after tracer injection. For each timepoint, 500 μL of
blood was transferred to a 13 × 75 mm plastic tube containing 75 USP sodium
heparin (Benton Dickinson Vacutainer 367871). A separate fraction of 500 μL
aliquot of blood was spun in a clinical centrifuge for 5 min at room temperature.
Two hundred microliter of the plasma fraction from this second aliquot was
transferred to a new Vacutainer tube. In order to match the volume of the whole
blood sample, water was added to the plasma fraction and to the cellular fraction to
a ﬁnal volume of 500 μL. The radioactive counts in whole blood (ﬁrst fraction), and
the plasma fractions were measured with a gamma counter (Perkin Elmer Wizard
1470). All blood counts were decay corrected to the time of tracer injection.
Dosimetry (OLINDA). Organ doses values were calculated using organ-level
internal dose assessment (OLINDA) software (Vanderbilt University, 2003)61. The
organs with highest uptake were included in the assessment. These include the
kidneys, stomach, small intestine and bladder. A threshold-based segmentation on
the last frame of dynamic PET images were used to determine ROIs for the kidney
and bladder due to their high tracer uptake relative to background. PET/CT overlay
images were used to manually trace ROIs of the stomach and small intestine.
Organs with lower uptake, were also included in the dosimetry assessment
including the pancreas, liver, lung, and heart. ROIs for these organs were also
determined manually on PET/CT overlay images. Muscle uptake was also included
in this study due to its large mass representation. In addition, a whole-body ROI
was determined by threshold-based segmentation with the baseline threshold value
set to exclude image noise occurring outside the body. ROIs were drawn in con-
sensus (by R.H.K, L.B, and F.H.). Normalized cumulative activity was determined
for each organ from the area under the curve (AUC) which was calculated using
the trapezoidal rule and assuming a physical decay only after the last measurement
divided by the total injected activity. These data were used to estimate the radiation
doses absorbed by all of the organs.
Immunohistochemistry. Formalin-ﬁxed parafﬁn-embedded tumor tissues were
sectioned at 5 µm thickness. All histologic sections were stained with standard
hematoxylin-eosin immunohistochemical staining (H&E). To conﬁrm the presence
of αvβ6, additional sections were stained with immunohistochemistry (IHC) for
anti-human αvβ6 (0.625 μg ml−1, 6.2A1, Biogen Idec, Cambridge, MA). For pre-
paration of IHC staining, the slides were deparafﬁnized with xylene and rehydrated
in serially diluted ethanol solutions (100–50%), followed by demineralized water
according to standard protocols. Endogenous peroxidase activity was blocked by
incubation in 0.3% hydrogen peroxide in phosphate buffered saline (PBS) for
20 min. Antigen retrieval for αvβ6 was performed with 0.4% pepsin incubation
(Dako) at 37 °C for 10 min. Following antigen retrieval, the tissue sections were
incubated overnight with the primary antibodies in 100 µl 1% BSA in PBS at room
temperature. The slides were washed with PBS, followed by incubation with sec-
ondary antibody at room temperature according to the Vectastain ABC HRP kit
(Peroxidase, Mouse IgG, Vector Laboratories Inc., Burlingame, CA). After addi-
tional washing, the staining was visualized with 3,3-diaminobenzidine tetra-
hydrochloride solution (DAKO, Glustrup, Denmark) at room temperature for
5 min and counterstained with hematoxylin for 20 s. Finally, the tissue sections
were dehydrated and mounted in Pertex (Histolab, Rockville, MD, USA).
[68Ga]NODAGA-R01-MG PET/CT imaging (PUMC Hospital). The following
study was conducted at Peking Union Medical College Hospital under local
Institutional Review Board oversight. This study is compliant with the guidance of
the Ministry of Science and Technology (MOST) for the review and approval of
human genetic resources. A dosage of ~2 mCi [68Ga]NODAGA-R01-MG was
administered to two adult male patients (lung and pancreatic cancer) and four
adult female patients (3 cervical and one pancreatic cancer) who were diagnosed
with cancer, as conﬁrmed by tissue biopsy (Figs. 4 and 5, Supplementary Table 11).
One patient reported nausea and vertigo ~1 h p.i.; the complaints lasted about an
hour and disappeared without treatment. The remaining six study subjects did not
report any adverse reactions, and none were observed by the attending physicians
and clinical researchers.
Study participants did not prepare in any way (i.e. fasting) for the imaging
study. Each patient, except for one (described below), underwent a single whole-
body static PET/CT scan at 29–60 min after intravenous injection of [68Ga]
NODAGA-R01-MG. The administered dose was 55.5–96.2MBq (1.5–2.6 mCi). The
scan (6 bed positions, 2 min bed−1) covered an area that included the top of the
skull to the middle of the femur. OSEM was applied for reconstruction. One patient
with cervical cancer underwent multiple sequential whole-body static PET scans.
For this cervical cancer patient, a single whole-body low-dose CT scan was
performed prior to tracer administration, which was used for reconstruction and as
an anatomical reference for the sequential PET images. The CT scan (140 kV,
35 mA, pitch of 1:1, layer of 5 mm thickness; layer spacing of 3 mm, 512*512
matrix, ﬁeld of view of 70 cm) also covered the top of the skull to the middle of the
femur. After the CT scan, the ﬁrst whole-body PET scan (6 bed positions, 2 min
bed−1) was acquired concurrent with the intraveneous administration of 77.7MBq
(2.1 mCi) [68Ga]NODAGA-R01-MG. Immediately upon completion of the ﬁrst
scan, the second whole-body static PET data was acquired. Sequentially, multiple
whole-body static PET scans were acquired, one by one, from 0 to 75 min. A total
of 6 whole-body static PET scans (6 beds of each timepoint) were performed in this
patient.
[18F]FDG PET/CT (PUMC Hospital). All patients were instructed to avoid
strenuous work or exercise for at least 24 h prior to the scheduled study date. Study
participants were also instructed to fast for at least 4 h before intravenous
administration of the PET tracer. Patients were administered [18F]FDG at a dosage
of 5.55 MBq (0.15 mCi) per kilogram body weight. Immediately after tracer
administration, patients were allowed to rest and relax in a warm, darkened room
for approximately 45–60 min. Next, each patient emptied their bladder. The PET
scan that followed spanned a region from the mid-thigh area to the base of the skull
(six bed positions, 2 min bed−1).
Region of interest. Upon co-registration of the PET and CT images, the CT
images were used to determine regions of interest for the organs or tissues reported
in the manuscript. These ROIs were applied to the PET images of the brain,
pituitary gland, breast, lower and upper large intestine, small intestine, stomach,
pancreas, heart wall, liver, lung, muscle, red marrow, bone, skin, and thyroid gland.
For high uptake organs such as the kidneys, bladder and for the whole body,
threshold-based segmentation of PET images were used to determine a close-ﬁtting
ROI around the entire organ or whole body. In order to determine accuracy, these
PET-derived ROIs were compared to the CT overlay for a close match. For the
pancreatic lesions, several ROIs for the knottin vs. FDG tracers were compared.
These data are reported as mean SUVs.
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Statistical analysis. All data are presented as the average value ± the SD of at
least three independent measurements. Statistical analysis for animal studies
and binding studies were performed by two factor ANOVA without replication
analysis using Microsoft Excel. Signiﬁcance was assigned for p values of
<0.05. Difference in SUV between healthy volunteers and IPF patients was
tested by an exact Wilcoxon ranksum test using Stata Release 15.1 (StataCorp
LP, College Station, TX). The correlation between left and right lungs was
estimated by an average absolute-agreement intraclass correlation from a
one-way random-effects model34. Due to high degree of correlation between the
two halves of the lungs, only the right ones were used to avoid the transplanted
left lung of IPF-4.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
Data availability
Source data for the following Figures, Supplementary Figs. and Supplementary Tables are
provided in a Source Data ﬁle, which include Figs. 1B, C, 4C, 6D, 7, Table 3 and
Supplementary Figs. 1B, 3C, 4B, 5B, 6, 8, 9, 10B, 11, 14 and Supplementary Tables 2, 3, 7,
8, 13. The NMR and crystal structures can be accessed at the protein data bank under
accession codes, 2N8B.pdb (https://doi.org/10.2210/pdb2N8B/pdb), 2N8C.pdb (https://
doi.org/10.2210/pdb2N8C/pdb), and 6CDX.pdb (https://doi.org/10.2210/pdb6CDX/
pdb), respectively.
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